Whole-life Investigation of Lishui Longevity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-80
SponsorThe Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital
About this trial
1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors. 2. To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent.
Disqualifiers
Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.
Trial population
The study population consists of 4,500 participants aged 30-80 years recruited from 10 urban and 10 rural sites in Lishui City using a cluster sampling method. Participants are randomly divided into three equal groups of 1,500 each, receiving different examination protocols. The collected data are further analyzed and grouped into cerebrovascular, tumor, and epigenetic age categories based on the respective test results.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
4,500 Participants
are grouped into 3 trial groupsGroup A: Cerebrovascular group
Group B: Tumor Group
Group C: Epigenetic Age Group
Trial outcomes
Primary outcomes
1
Prevalence rate of stroke and tumors
A blood-based methylation pan-cancer assay was performed to screen for ten common malignancies, including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. The prevalence of each cancer type was calculated as the number of confirmed positive cases divided by the total number of participants screened.
Time frame
From enrollment to the end of the 10-year follow-up periodSecondary outcomes
1
Unilateral carotid artery stenosis rate
The degree of cervical vascular stenosis was detected and evaluated. The distribution of unilateral carotid artery stenosis rate (defined as stenosis degree \>50%) was analyzed, which was calculated as the number of participants with carotid stenosis greater than 50% divided by the total screened population.
Time frame
From enrollment to the end of the 10-year follow-up periodSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov